- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, SCD1 Inhibitor MTI-301
- Procedure · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2257–2280
of 29,142
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load, HIV Antibodies
- Interventions
- VRC-HIVMAB060-00-AB
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
- Conditions
- Healthy Volunteer
- Interventions
- Moxifloxacin, RO4917838, RO4917838 placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 169 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Eosinophilic Asthma
- Interventions
- ICS-LABA, benralizumab, Placebo for Benralizumab
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more
- Conditions
- Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
- Interventions
- Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Influenza Immunization
- Interventions
- Pandemic flu H5 mRNA vaccine, Placebo
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
- Conditions
- Primary Biliary Cirrhosis (PBC)
- Interventions
- Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 16 more
- Conditions
- Generalized Anxiety Disorder, Seroquel XR
- Interventions
- Seroquel XR
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Hypertension
- Interventions
- CIN-107
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Tampa, Florida
- Conditions
- Yellow Fever Vaccination Reaction
- Interventions
- Yellow Fever Vaccine
- Biological
- Lead sponsor
- US Army Medical Research Institute of Infectious Diseases
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- End Stage Renal Disease
- Interventions
- Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Melanoma
- Interventions
- Pembrolizumab, Interleukin-2
- Drug
- Lead sponsor
- Ralph Hauke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Diabetic Macular Edema
- Interventions
- iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Environmental Exposure
- Interventions
- [14C]-benzo[a]pyrene
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Neoplasms
- Interventions
- NY-ESO-1(c259)T Cells, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Tumors
- Interventions
- Sunitinib malate, Rapamycin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neuroblastoma
- Interventions
- anti-thymocyte globulin, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation
- Other · Drug · Procedure
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York • Columbus, Ohio + 1 more
- Conditions
- Alcohol Risk Behaviors
- Interventions
- Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- Michael J. Wesley, PhD
- Other
- Eligibility
- 21 Years to 29 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Breast Cancer
- Interventions
- High Dose Vitamin D, Placebo, Standard Dose Vitamin D3, Letrozole 2.5mg
- Dietary Supplement · Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Westwood, Kansas • Wichita, Kansas
- Conditions
- Shigellosis
- Interventions
- Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
- Biological
- Lead sponsor
- LimmaTech Biologics AG
- Industry
- Eligibility
- 8 Months to 50 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 0
- States / cities
- Not listed
- Conditions
- Radius Fracture Distal, Hematoma, Lidocaine, Pediatrics
- Interventions
- Lidocaine 1% Injectable Solution
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 5 Years to 17 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cancer, Lymphoma
- Interventions
- XL844, Gemcitabine
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas